‘Challenging’ Times For Sandoz As COVID Bites

Sales And Core Operating Profit See Double-Digit Declines Despite Biopharma Growth

 
• By David Wallace
  
COVID coronavirus impact graph recovery
Sandoz expects its business to stabilize as pandemic pressures ease • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business